Pediatric Antipsychotic Medication | Learning BCBA CEU Credits: 2

Syllabus

Pediatric Antipsychotic Medication

Learning Objectives

1. Identify common pediatric psychiatric disorders and their diagnostic criteria.
2. Differentiate between typical and atypical antipsychotic medications.
3. Understand the implications of off-label use and key considerations in medication management
   for children.
4. Analyze case studies to apply knowledge in practical scenarios.

Author/Speaker

Dr. Polina Kalmanovich is a Vice President, Head of Global Program Management at Sarepta Pharmaceuticals. Prior to joining Sarepta, Polina served as the Head of Regulatory and Quality of Novus Therapeutics (an Ear Nose and Throat focused biotechnology company). Prior to joining Novus, Polina worked as a Regulatory Lead in Chase Pharmaceuticals, an Alzheimer’s focused company. She worked at Allergan for over 15 years in total and has been effective in leading global development and registrations in several therapeutic indications, including neurology, infectious disease, pain, urology, and psychiatry. She possesses strong collaborative interpersonal skills, is ethical, trustworthy, reliable and self-motivated. She has outstanding organizational, negotiation and communication skills (verbal and written). She is seen as a highly effective and passionate communicator. She has successfully demonstrated the ability to develop and execute regulatory strategy to achieve key project objectives.
Dr. Kalmanovich holds a Bachelor of Science Degree from the University of California Irvine, a Doctor of Pharmacy Degree and a Master’s of Regulatory Science from the University of Southern California. Most recently, she completed a specialization in leadership and management program from the Harvard Business School and is a graduate of the Harvard Business School’s General Management Program GMP 31.